The CamSol method of rational design of protein mutants with enhanced solubility.

Protein solubility is often an essential requirement in biotechnological and biomedical applications. Great advances in understanding the principles that determine this specific property of proteins have been made during the past decade, in particular concerning the physicochemical characteristics of their constituent amino acids. By exploiting these advances, we present the CamSol method for the rational design of protein variants with enhanced solubility. The method works by performing a rapid computational screening of tens of thousand of mutations to identify those with the greatest impact on the solubility of the target protein while maintaining its native state and biological activity. The application to a single-domain antibody that targets the Alzheimer's Aβ peptide demonstrates that the method predicts with great accuracy solubility changes upon mutation, thus offering a cost-effective strategy to help the production of soluble proteins for academic and industrial purposes.

[1]  A. Villaverde,et al.  Protein quality in bacterial inclusion bodies. , 2006, Trends in biotechnology.

[2]  R. Kopito,et al.  Aggresomes, inclusion bodies and protein aggregation. , 2000, Trends in cell biology.

[3]  Michele Vendruscolo,et al.  Prediction of aggregation-prone regions in structured proteins. , 2008, Journal of molecular biology.

[4]  Bernhardt L. Trout,et al.  Design of therapeutic proteins with enhanced stability , 2009, Proceedings of the National Academy of Sciences.

[5]  P. Carter,et al.  Introduction to current and future protein therapeutics: a protein engineering perspective. , 2011, Experimental cell research.

[6]  C. Dobson,et al.  Hsp70 Oligomerization Is Mediated by an Interaction between the Interdomain Linker and the Substrate-Binding Domain , 2013, PloS one.

[7]  J. García de la Torre,et al.  Calculation of hydrodynamic properties of globular proteins from their atomic-level structure. , 2000, Biophysical journal.

[8]  Dmitrij Frishman,et al.  PROSO II – a new method for protein solubility prediction , 2012, The FEBS journal.

[9]  Brian M. Murphy,et al.  Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.

[10]  S. Sidhu.  Phage display in pharmaceutical biotechnology. , 2000, Current opinion in biotechnology.

[11]  Michael Goodman.  Market watch: Sales of biologics to show robust growth through to 2013 , 2009, Nature Reviews Drug Discovery.

[12]  M. Morbidelli,et al.  Aggregation Stability of a Monoclonal Antibody During Downstream Processing , 2011, Pharmaceutical Research.

[13]  C. Dobson,et al.  Rationalization of the effects of mutations on peptide andprotein aggregation rates , 2003, Nature.

[14]  M. Vendruscolo,et al.  Subdomain architecture and stability of a giant repeat protein. , 2013, The journal of physical chemistry. B.

[15]  Brian Kuhlman,et al.  Structure-based design of supercharged, highly thermoresistant antibodies. , 2012, Chemistry & biology.

[16]  C. J. Bond,et al.  Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains* , 2008, Journal of Biological Chemistry.

[17]  Daniel E. Otzen,et al.  Protein drug stability: a formulation challenge , 2005, Nature Reviews Drug Discovery.

[18]  P. Tessier,et al.  Toward aggregation-resistant antibodies by design. , 2013, Trends in biotechnology.

[19]  A. Sali,et al.  Modeller: generation and refinement of homology-based protein structure models. , 2003, Methods in enzymology.

[20]  C. Pace,et al.  Measuring and increasing protein solubility. , 2008, Journal of pharmaceutical sciences.

[21]  Steven J Shire,et al.  Formulation and manufacturability of biologics. , 2009, Current opinion in biotechnology.

[22]  H. P. Sørensen,et al.  Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli , 2005 .

[23]  C. F. van der Walle,et al.  Therapeutic antibodies: market considerations, disease targets and bioprocessing. , 2013, International journal of pharmaceutics.

[24]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[25]  G. Petersen,et al.  Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. , 2006, Protein expression and purification.

[26]  Michele Vendruscolo,et al.  Physicochemical principles that regulate the competition between functional and dysfunctional association of proteins , 2009, Proceedings of the National Academy of Sciences.

[27]  Dan S. Tawfik,et al.  Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Pascal Benkert,et al.  QMEAN server for protein model quality estimation , 2009, Nucleic Acids Res..

[29]  G. Winter,et al.  Making antibodies by phage display technology. , 1994, Annual review of immunology.

[30]  R. Vessella,et al.  Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility. , 1998, Immunotechnology : an international journal of immunological engineering.

[31]  D. Christ,et al.  Stability engineering of the human antibody repertoire , 2014, FEBS letters.

[32]  Stephen H. White,et al.  Experimentally determined hydrophobicity scale for proteins at membrane interfaces , 1996, Nature Structural Biology.

[33]  P. Carter.  Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[34]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[35]  C. Dobson.  Protein folding and misfolding , 2003, Nature.

[36]  D. Stock,et al.  General strategy for the generation of human antibody variable domains with increased aggregation resistance , 2012, Proceedings of the National Academy of Sciences.

[37]  A. Pavlou,et al.  Recombinant protein therapeutics—success rates, market trends and values to 2010 , 2004, Nature Biotechnology.

[38]  David E. Golan,et al.  Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.

[39]  P. Tessier,et al.  Engineering aggregation-resistant antibodies. , 2012, Annual review of chemical and biomolecular engineering.

[40]  Andreas Bracher,et al.  Molecular chaperones in protein folding and proteostasis , 2011, Nature.

[41]  Michele Vendruscolo,et al.  Sequence-based prediction of protein solubility. , 2012, Journal of molecular biology.

[42]  A. Plückthun,et al.  Selection for improved protein stability by phage display. , 1999, Journal of molecular biology.

[43]  P. Tessier,et al.  Structure-based design of conformation- and sequence-specific antibodies against amyloid β , 2011, Proceedings of the National Academy of Sciences.

[44]  G. Waldo,et al.  Genetic screens and directed evolution for protein solubility. , 2003, Current opinion in chemical biology.

[45]  H. Hoogenboom,et al.  Selecting and screening recombinant antibody libraries , 2005, Nature Biotechnology.

[46]  M. Bagajewicz,et al.  Predicting the solubility of recombinant proteins in Escherichia coli. , 2015, Methods in molecular biology.

[47]  C. Dobson,et al.  Widespread aggregation and neurodegenerative diseases are associated with supersaturated proteins. , 2013, Cell reports.

[48]  John McCafferty,et al.  Beyond natural antibodies: the power of in vitro display technologies , 2011, Nature Biotechnology.

[49]  L. Serrano,et al.  Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins , 2004, Nature Biotechnology.

[50]  S. Brenner,et al.  The critical concentration of actin in the presence of ATP increases with the number concentration of filaments and approaches the critical concentration of actin.ADP. , 1984, The Journal of biological chemistry.

[51]  F. Baneyx,et al.  Recombinant protein folding and misfolding in Escherichia coli , 2004, Nature Biotechnology.

[52]  Michele Vendruscolo,et al.  Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. , 2005, Journal of molecular biology.

[53]  D. Raleigh,et al.  Rational design of potent domain antibody inhibitors of amyloid fibril assembly , 2012, Proceedings of the National Academy of Sciences.

[54]  Richard I. Morimoto,et al.  Adapting Proteostasis for Disease Intervention , 2008, Science.

[55]  Pierre Baldi,et al.  SOLpro: accurate sequence-based prediction of protein solubility , 2009, Bioinform..

[56]  G. Winter,et al.  Aggregation-resistant domain antibodies selected on phage by heat denaturation , 2004, Nature Biotechnology.

[57]  R G Harrison,et al.  New fusion protein systems designed to give soluble expression in Escherichia coli. , 1999, Biotechnology and bioengineering.

[58]  G. Winter,et al.  Thermodynamically stable aggregation-resistant antibody domains through directed evolution. , 2008, Journal of molecular biology.

[59]  Sandeep Kumar,et al.  Potential aggregation prone regions in biotherapeutics , 2009, mAbs.